Liraglutide and Renal Outcomes in Type 2 Diabetes
In a randomized, controlled trial, liraglutide (a glucagon-like peptide 1 receptor agonist) or placebo was added to usual care in patients with type 2 diabetes. In secondary analyses, rates of development and progression of diabetic kidney disease were lower with liraglutide.
Gespeichert in:
| Veröffentlicht in: | NEW ENGLAND JOURNAL OF MEDICINE 2017-08, Vol.377 (9), p.839-848 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 848 |
|---|---|
| container_issue | 9 |
| container_start_page | 839 |
| container_title | NEW ENGLAND JOURNAL OF MEDICINE |
| container_volume | 377 |
| creator | Mann, Johannes F.E Ørsted, David D Brown-Frandsen, Kirstine Marso, Steven P Poulter, Neil R Rasmussen, Søren Tornøe, Karen Zinman, Bernard Buse, John B |
| description | In a randomized, controlled trial, liraglutide (a glucagon-like peptide 1 receptor agonist) or placebo was added to usual care in patients with type 2 diabetes. In secondary analyses, rates of development and progression of diabetic kidney disease were lower with liraglutide. |
| doi_str_mv | 10.1056/NEJMoa1616011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_494403</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1934281581</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-8603aff499d6a0c4e836ee2544a91ca380d6ac7fc72a427a5974e94f402d17993</originalsourceid><addsrcrecordid>eNp1kM1Lw0AQxRdRbK0evUpABC_R_Zgku0ep9YtqQep52W4mkpqPmk2Q_veupFYUnMsMw4_He4-QY0YvGI3iy6fJw2NtWMxiytgOGbJIiBCAxrtkSCmXISRKDMiBc0vqh4HaJwMuZQRURkPCpnljXouuzVMMTJUGz1iZIph1ra1LdEFeBfP1CgMeXOdmgS26Q7KXmcLh0WaPyMvNZD6-C6ez2_vx1TS0wGUbypgKk2WgVBobagGliBF5BGAUs0ZI6v82yWzCDfDERCoBVJAB5SlLlBIjEva67gNX3UKvmrw0zVrXJteb15u_UIPycYXnz3t-1dTvHbpWl7mzWBSmwrpzminhjbFIMo-e_kGXddf43D1FhS-T_xiwTe1cg9nWAqP6q3v9q3vPn2xUu0WJ6Zb-LtsDZz1Qlk5XuCz_EfoEzsGHfA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1934031602</pqid></control><display><type>article</type><title>Liraglutide and Renal Outcomes in Type 2 Diabetes</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SWEPUB Freely available online</source><source>New England Journal of Medicine</source><creator>Mann, Johannes F.E ; Ørsted, David D ; Brown-Frandsen, Kirstine ; Marso, Steven P ; Poulter, Neil R ; Rasmussen, Søren ; Tornøe, Karen ; Zinman, Bernard ; Buse, John B</creator><creatorcontrib>Mann, Johannes F.E ; Ørsted, David D ; Brown-Frandsen, Kirstine ; Marso, Steven P ; Poulter, Neil R ; Rasmussen, Søren ; Tornøe, Karen ; Zinman, Bernard ; Buse, John B ; LEADER Steering Committee and Investigators</creatorcontrib><description>In a randomized, controlled trial, liraglutide (a glucagon-like peptide 1 receptor agonist) or placebo was added to usual care in patients with type 2 diabetes. In secondary analyses, rates of development and progression of diabetic kidney disease were lower with liraglutide.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1616011</identifier><identifier>PMID: 28854085</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Acute Kidney Injury - prevention & control ; Aged ; Albuminuria - prevention & control ; Antidiabetics ; Cardiovascular diseases ; Cerebral infarction ; Clinical outcomes ; Creatinine ; Creatinine - blood ; Death ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetic Nephropathies - drug therapy ; Diabetic Nephropathies - mortality ; Diabetic Nephropathies - prevention & control ; Double-Blind Method ; Drug therapy ; End-stage renal disease ; Female ; Follow-Up Studies ; Glomerular Filtration Rate ; Glucagon ; Glucagon-like peptide 1 ; Glucagon-Like Peptide 1 - agonists ; Humans ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Intention to Treat Analysis ; Kidney diseases ; Kidney Failure, Chronic - prevention & control ; Kidney transplantation ; Liraglutide - adverse effects ; Liraglutide - therapeutic use ; Long-term effects ; Male ; Middle Aged ; Myocardial infarction ; Patients ; Risk factors ; Stroke</subject><ispartof>NEW ENGLAND JOURNAL OF MEDICINE, 2017-08, Vol.377 (9), p.839-848</ispartof><rights>Copyright © 2017 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-8603aff499d6a0c4e836ee2544a91ca380d6ac7fc72a427a5974e94f402d17993</citedby><cites>FETCH-LOGICAL-c428t-8603aff499d6a0c4e836ee2544a91ca380d6ac7fc72a427a5974e94f402d17993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1616011$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa1616011$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>230,314,550,776,780,881,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28854085$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:136481339$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Mann, Johannes F.E</creatorcontrib><creatorcontrib>Ørsted, David D</creatorcontrib><creatorcontrib>Brown-Frandsen, Kirstine</creatorcontrib><creatorcontrib>Marso, Steven P</creatorcontrib><creatorcontrib>Poulter, Neil R</creatorcontrib><creatorcontrib>Rasmussen, Søren</creatorcontrib><creatorcontrib>Tornøe, Karen</creatorcontrib><creatorcontrib>Zinman, Bernard</creatorcontrib><creatorcontrib>Buse, John B</creatorcontrib><creatorcontrib>LEADER Steering Committee and Investigators</creatorcontrib><title>Liraglutide and Renal Outcomes in Type 2 Diabetes</title><title>NEW ENGLAND JOURNAL OF MEDICINE</title><addtitle>N Engl J Med</addtitle><description>In a randomized, controlled trial, liraglutide (a glucagon-like peptide 1 receptor agonist) or placebo was added to usual care in patients with type 2 diabetes. In secondary analyses, rates of development and progression of diabetic kidney disease were lower with liraglutide.</description><subject>Acute Kidney Injury - prevention & control</subject><subject>Aged</subject><subject>Albuminuria - prevention & control</subject><subject>Antidiabetics</subject><subject>Cardiovascular diseases</subject><subject>Cerebral infarction</subject><subject>Clinical outcomes</subject><subject>Creatinine</subject><subject>Creatinine - blood</subject><subject>Death</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetic Nephropathies - drug therapy</subject><subject>Diabetic Nephropathies - mortality</subject><subject>Diabetic Nephropathies - prevention & control</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>End-stage renal disease</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glomerular Filtration Rate</subject><subject>Glucagon</subject><subject>Glucagon-like peptide 1</subject><subject>Glucagon-Like Peptide 1 - agonists</subject><subject>Humans</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Intention to Treat Analysis</subject><subject>Kidney diseases</subject><subject>Kidney Failure, Chronic - prevention & control</subject><subject>Kidney transplantation</subject><subject>Liraglutide - adverse effects</subject><subject>Liraglutide - therapeutic use</subject><subject>Long-term effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myocardial infarction</subject><subject>Patients</subject><subject>Risk factors</subject><subject>Stroke</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><sourceid>D8T</sourceid><recordid>eNp1kM1Lw0AQxRdRbK0evUpABC_R_Zgku0ep9YtqQep52W4mkpqPmk2Q_veupFYUnMsMw4_He4-QY0YvGI3iy6fJw2NtWMxiytgOGbJIiBCAxrtkSCmXISRKDMiBc0vqh4HaJwMuZQRURkPCpnljXouuzVMMTJUGz1iZIph1ra1LdEFeBfP1CgMeXOdmgS26Q7KXmcLh0WaPyMvNZD6-C6ez2_vx1TS0wGUbypgKk2WgVBobagGliBF5BGAUs0ZI6v82yWzCDfDERCoBVJAB5SlLlBIjEva67gNX3UKvmrw0zVrXJteb15u_UIPycYXnz3t-1dTvHbpWl7mzWBSmwrpzminhjbFIMo-e_kGXddf43D1FhS-T_xiwTe1cg9nWAqP6q3v9q3vPn2xUu0WJ6Zb-LtsDZz1Qlk5XuCz_EfoEzsGHfA</recordid><startdate>20170831</startdate><enddate>20170831</enddate><creator>Mann, Johannes F.E</creator><creator>Ørsted, David D</creator><creator>Brown-Frandsen, Kirstine</creator><creator>Marso, Steven P</creator><creator>Poulter, Neil R</creator><creator>Rasmussen, Søren</creator><creator>Tornøe, Karen</creator><creator>Zinman, Bernard</creator><creator>Buse, John B</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20170831</creationdate><title>Liraglutide and Renal Outcomes in Type 2 Diabetes</title><author>Mann, Johannes F.E ; Ørsted, David D ; Brown-Frandsen, Kirstine ; Marso, Steven P ; Poulter, Neil R ; Rasmussen, Søren ; Tornøe, Karen ; Zinman, Bernard ; Buse, John B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-8603aff499d6a0c4e836ee2544a91ca380d6ac7fc72a427a5974e94f402d17993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acute Kidney Injury - prevention & control</topic><topic>Aged</topic><topic>Albuminuria - prevention & control</topic><topic>Antidiabetics</topic><topic>Cardiovascular diseases</topic><topic>Cerebral infarction</topic><topic>Clinical outcomes</topic><topic>Creatinine</topic><topic>Creatinine - blood</topic><topic>Death</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetic Nephropathies - drug therapy</topic><topic>Diabetic Nephropathies - mortality</topic><topic>Diabetic Nephropathies - prevention & control</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>End-stage renal disease</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glomerular Filtration Rate</topic><topic>Glucagon</topic><topic>Glucagon-like peptide 1</topic><topic>Glucagon-Like Peptide 1 - agonists</topic><topic>Humans</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Intention to Treat Analysis</topic><topic>Kidney diseases</topic><topic>Kidney Failure, Chronic - prevention & control</topic><topic>Kidney transplantation</topic><topic>Liraglutide - adverse effects</topic><topic>Liraglutide - therapeutic use</topic><topic>Long-term effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myocardial infarction</topic><topic>Patients</topic><topic>Risk factors</topic><topic>Stroke</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mann, Johannes F.E</creatorcontrib><creatorcontrib>Ørsted, David D</creatorcontrib><creatorcontrib>Brown-Frandsen, Kirstine</creatorcontrib><creatorcontrib>Marso, Steven P</creatorcontrib><creatorcontrib>Poulter, Neil R</creatorcontrib><creatorcontrib>Rasmussen, Søren</creatorcontrib><creatorcontrib>Tornøe, Karen</creatorcontrib><creatorcontrib>Zinman, Bernard</creatorcontrib><creatorcontrib>Buse, John B</creatorcontrib><creatorcontrib>LEADER Steering Committee and Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>NEW ENGLAND JOURNAL OF MEDICINE</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mann, Johannes F.E</au><au>Ørsted, David D</au><au>Brown-Frandsen, Kirstine</au><au>Marso, Steven P</au><au>Poulter, Neil R</au><au>Rasmussen, Søren</au><au>Tornøe, Karen</au><au>Zinman, Bernard</au><au>Buse, John B</au><aucorp>LEADER Steering Committee and Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liraglutide and Renal Outcomes in Type 2 Diabetes</atitle><jtitle>NEW ENGLAND JOURNAL OF MEDICINE</jtitle><addtitle>N Engl J Med</addtitle><date>2017-08-31</date><risdate>2017</risdate><volume>377</volume><issue>9</issue><spage>839</spage><epage>848</epage><pages>839-848</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>In a randomized, controlled trial, liraglutide (a glucagon-like peptide 1 receptor agonist) or placebo was added to usual care in patients with type 2 diabetes. In secondary analyses, rates of development and progression of diabetic kidney disease were lower with liraglutide.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>28854085</pmid><doi>10.1056/NEJMoa1616011</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | NEW ENGLAND JOURNAL OF MEDICINE, 2017-08, Vol.377 (9), p.839-848 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_494403 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SWEPUB Freely available online; New England Journal of Medicine |
| subjects | Acute Kidney Injury - prevention & control Aged Albuminuria - prevention & control Antidiabetics Cardiovascular diseases Cerebral infarction Clinical outcomes Creatinine Creatinine - blood Death Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 - drug therapy Diabetic Nephropathies - drug therapy Diabetic Nephropathies - mortality Diabetic Nephropathies - prevention & control Double-Blind Method Drug therapy End-stage renal disease Female Follow-Up Studies Glomerular Filtration Rate Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide 1 - agonists Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Intention to Treat Analysis Kidney diseases Kidney Failure, Chronic - prevention & control Kidney transplantation Liraglutide - adverse effects Liraglutide - therapeutic use Long-term effects Male Middle Aged Myocardial infarction Patients Risk factors Stroke |
| title | Liraglutide and Renal Outcomes in Type 2 Diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T04%3A13%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liraglutide%20and%20Renal%20Outcomes%20in%20Type%202%20Diabetes&rft.jtitle=NEW%20ENGLAND%20JOURNAL%20OF%20MEDICINE&rft.au=Mann,%20Johannes%20F.E&rft.aucorp=LEADER%20Steering%20Committee%20and%20Investigators&rft.date=2017-08-31&rft.volume=377&rft.issue=9&rft.spage=839&rft.epage=848&rft.pages=839-848&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa1616011&rft_dat=%3Cproquest_swepu%3E1934281581%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1934031602&rft_id=info:pmid/28854085&rfr_iscdi=true |